Diagnosis and treatment of a patient with both psychotic and obsessive-compulsive symptoms

American Journal of Psychiatry

Volumn 167, Issue 7, 2010, Pages 754-761

  Rodriguez, Carolyn I ^a   Corcoran, Cheryl ^a   Simpson, Helen Blair ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LAMOTRIGINE; OLANZAPINE; PAROXETINE; RISPERIDONE; SERTRALINE;

ADULT; CASE REPORT; COGNITIVE THERAPY; COMORBIDITY; COMPETITIVE INHIBITION; COMPULSION; CONFERENCE PAPER; DELUSION; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DRUG DOSE TITRATION; EMERGENCY WARD; FAMILY HISTORY; HUMAN; LOW DRUG DOSE; MALE; MENTAL PATIENT; OBSESSIVE COMPULSIVE DISORDER; ONSET AGE; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHIATRIC TREATMENT; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; REMISSION; SCHIZOPHRENIA; SOCIAL PSYCHOLOGY; SYMPTOM; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VISUAL HALLUCINATION;

AGE OF ONSET; ANTIPSYCHOTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954236018     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2009.09070997     Document Type: Conference Paper

References (70)

1. Reznik I, Yavin I, Stryjer R, Spivak B, Gonen N, Strous R, Mester R, Weizman A, Kotler M: Clozapine in the treatment of obsessive-compulsive symptoms in schizophrenia patients: a case series study. Pharmacopsychiatry 2004; 37:52-56 (Pubitemid 38651017)
2. Poyurovsky M, Glick I, Koran L: Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms. J Psychopharmacol (Epub ahead of print, Dec 12, 2008)
3. Niendam TA, Berzak J, Cannon TD, Bearden CE: Obsessive compulsive symptoms in the psychosis prodrome: correlates of clinical and functional outcome. Schizophr Res 2009; 108:170-175
4. Poyurovsky M, Weizman A, Weizman R: Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs 2004; 18:989-1010 (Pubitemid 39612010)
5. Fenton WS, McGlashan TH: The prognostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry 1986; 143:437-441 (Pubitemid 16119747)
6. Berman I, Kalinowski A, Berman SM, Lengua J, Green AI: Obsessive and compulsive symptoms in chronic schizophrenia. Compr Psychiatry 1995; 36:6-10
7. Sevincok L, Akoglu A, Kokcu F: Suicidality in schizophrenic patients with and without obsessive-compulsive disorder. Schizophr Res 2007; 90:198-202 (Pubitemid 46177549)
8. Kozak MJ, Foa EB: Obsessions, overvalued ideas, and delusions in obsessive-compulsive disorder. Behav Res Ther 1994; 32:343-353
9. Ravi Kishore V, Samar R, Janardhan Reddy YC, Chandrasekhar CR, Thennarasu K: Clinical characteristics and treatment response in poor and good insight obsessive-compulsive disorder. Eur Psychiatry 2004; 19:202-208 (Pubitemid 38766133)
10. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision (DSM-IV-TR). Washington, DC, American Psychiatric Association, 1994
11. Lewis S, Escalona PR, Keith SJ: Phenomenology of schizophrenia, in Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 9th ed. Edited by Sadock BJ, Sadock VA, Ruiz P. Philadelphia, Lippincott Williams & Wilkins, 2009, pp 1434-1435
12. Foa EB, Kozak MJ: DSM-IV field trial: obsessive-compulsive disorder. Am J Psychiatry 1995; 152:90-96; correction, 152:654
13. Tracy JI, de Leon J, Qureshi G, McCann EM, McGrory A, Josiassen RC: Repetitive behaviors in schizophrenia: a single disturbance or discrete symptoms? Schizophr Res 1996; 20:221-229
14. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593-602 (Pubitemid 40973434)
15. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Schizophrenia, 2nd ed. Am J Psychiatry 2004; 161(Feb suppl)
16. Chang HH, Berman I: Treatment issues for patients with schizophrenia who have obsessive-compulsive symptoms. Psychiatr Ann 1999; 29:529-532
17. Bloch MH, Landeros-Weisenberger A, Rosario MC, Pittenger C, Leckman JF: Meta-analysis of the symptom structure of obsessive-compulsive disorder. Am J Psychiatry 2008; 165:1532-1542
18. Mullins S, Spence SA: Re-examining thought insertion: semi-structured literature review and conceptual analysis. Br J Psychiatry 2003; 182:293-298 (Pubitemid 36408279)
19. Matussek P: [Studies on delusional perception, I: changes of the perceived external world in incipient primary delusion.] Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr 1952; 189:279-319 (German)
20. Jaspers K: General Psychopathology. Edited by Hoenig J, Hamilton M. Manchester, UK, Manchester University Press, 1963
21. Stephens GL, Graham G: Self-consciousness, mental agency, and the clincal psychopathology of thought insertion. Philosophy Psychiatry Psychol 1994; 1:1-10
22. Corcoran C, Davidson L, Sills-Shahar R, Nickou C, Malaspina D, Miller T, McGlashan T: A qualitative research study of the evolution of symptoms in individuals identified as prodromal to psychosis. Psychiatr Q 2003; 74:313-332 (Pubitemid 38095965)
23. Corcoran C, Gerson R, Sills-Shahar R, Nickou C, McGlashan T, Malaspina D, Davidson L: Trajectory to a first episode of psychosis: a qualitative research study with families. Early Interv Psychiatry 2007; 1:308-315
24. Bota RG, Munro JS, Ricci WF, Bota DA: The dynamics of insight in the prodrome of schizophrenia. CNS Spectr 2006; 11:355-362
25. Lappin JM, Morgan KD, Valmaggia LR, Broome MR, Woolley JB, Johns LC, Tabraham P, Bramon E, McGuire PK: Insight in individuals with an at risk mental state. Schizophr Res 2007; 90:238-244 (Pubitemid 46188522)
26. Eisen JL, Beer DA, Pato MT, Venditto TA, Rasmussen SA: Obsessive-compulsive disorder in patients with schizophrenia or schizoaffective disorder. Am J Psychiatry 1997; 154:271-273 (Pubitemid 27053739)
27. Levinson DF, Mowry BJ: Defining the schizophrenia spectrum: issues for genetic linkage studies. Schizophr Bull 1991; 17:491-514
28. Samuels JF, Riddle MA, Greenberg BD, Fyer AJ, McCracken JT, Rauch SL, Murphy DL, Grados MA, Pinto A, Knowles JA, Piacentini J, Cannistraro PA, Cullen B, Bienvenu OJ 3rd, Rasmussen SA, Pauls DL, Willour VL, Shugart YY, Liang KY, Hoehn-Saric R, Nestadt G: The OCD Collaborative Genetics Study: methods and sample description. Am J Med Genet B Neuropsychiatr Genet 2006; 141B:201-207
29. Huppert JD, Simpson HB, Nissenson KJ, Liebowitz MR, Foa EB: Quality of life and functional impairment in obsessive-compulsive disorder: a comparison of patients with and without comorbidity, patients in remission, and healthy controls. Depress Anxiety 2009; 26:39-45
30. Bellack AS, Morrison RL, Wixted JT, Mueser KT: An analysis of social competence in schizophrenia. Br J Psychiatry 1990; 156:809-818
31. Pinkham AE, Penn DL, Perkins DO, Lieberman J: Implications for the neural basis of social cognition for the study of schizophrenia. Am J Psychiatry 2003; 160:815-824
32. Couture SM, Penn DL, Roberts DL: The functional significance of social cognition in schizophrenia: a review. Schizophr Bull 2006; 32(suppl 1):S44-S63
33. Meares A: The diagnosis of prepsychotic schizophrenia. Lancet 1959; 1:55-58
34. Jones P, Rodgers B, Murray R, Marmot M: Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 1994; 344:1398-1402
35. Done DJ, Crow TJ, Johnstone EC, Sacker A: Childhood antecedents of schizophrenia and affective illness: social adjustment at ages 7 and 11. BMJ 1994; 309:699-703
36. Hans SL, Auerbach JG , Asarnow JR, Styr B, Marcus J: Social adjustment of adolescents at risk for schizophrenia: the Jerusalem Infant Development Study. J Am Acad Child Adolesc Psychiatry 2000; 39:1406-1414
37. Dworkin RH, Green SR, Small NE, Warner ML, Cornblatt BA, Erlenmeyer-Kimling L: Positive and negative symptoms and social competence in adolescents at risk for schizophrenia and affective disorder. Am J Psychiatry 1990; 147:1234-1236
38. Cornblatt BA, Lencz T, Smith CW, Correll CU, Auther AM, Nakayama E: The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bull 2003; 29:633-651 (Pubitemid 38181947)
39. Cornblatt BA, Auther AM, Niendam T, Smith CW, Zinberg J, Bearden CE, Cannon TD: Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr Bull 2007; 33:688-702 (Pubitemid 47343730)
40. Sobel W, Wolski R, Cancro R, Makari GJ: Interpersonal relatedness and paranoid schizophrenia (case conf). Am J Psychiatry 1996; 153:1084-1087 (Pubitemid 26264710)
41. Ongur D, Goff DC: Obsessive-compulsive symptoms in schizophrenia: associated clinical features, cognitive function, and medication status. Schizophr Res 2005; 75:349-362 (Pubitemid 40693067)
42. Rector NA, Beck AT: Cognitive behavioral therapy for schizophrenia: an empirical review. J Nerv Ment Dis 2001; 189:278-287 (Pubitemid 32448649)
43. Dickerson FB, Lehman AF: Evidence-based psychotherapy for schizophrenia. J Nerv Ment Dis 2006; 194:3-9
44. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder. Am J Psychiatry 2007; 164( Jul suppl)
45. McDougle CJ, Barr LC, Goodman WK, Pelton GH, Aronson SC, Anand A, Price LH: Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 1995; 152:1812-1814
46. Kozak MJ, Foa EB: Mastery of Obsessive-Compulsive Disorder: A Cognitive Behavioral Approach: Therapist Guide. Oxford, England, Oxford University Press, 1997
47. Lavin MR, Halligan P: ECT for comorbid obsessive-compulsive disorder and schizophrenia (letter). Am J Psychiatry 1996; 153:1652-1653 (Pubitemid 26406182)
48. Krystal JH, Perry EB Jr, Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A, Cooper TB, MacDougall L, Abi-Saab W, D'Souza DC: Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 2005; 62:985-994 (Pubitemid 41248378)
49. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH: Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-d-aspartate receptor antagonists. Arch Gen Psychiatry 2000; 57:270-276 (Pubitemid 30140436)
50. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 2007; 13:1102-1107 (Pubitemid 47517511)
51. Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S: Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005; 30:1735-1740
52. Pittenger C, Krystal JH, Coric V: Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006; 3:69-81 (Pubitemid 43276634)
53. Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH: Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005; 58:424-428 (Pubitemid 41219711)
54. Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ: Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000; 39:1096-1103
55. Aboujaoude E, Barry JJ, Gamel N: Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol 2009; 29:51-55
56. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK: A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63:856-864 (Pubitemid 44188478)
57. Schobel SA, Lewandowski NM, Corcoran CM, Moore H, Brown T, Malaspina D, Small SA: Differential targeting of the CA1 sub-field of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry 2009; 66:938-946
58. Javitt DC: Glutamate and schizophrenia: phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 2007; 78:69-108
59. Tiihonen J, Hallikainen T, Ryynänen OP, Repo-Tiihonen E, Kotilainen I, Eronen M, Toivonen P, Wahlbeck K, Putkonen A: Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 2003; 54:1241-1248 (Pubitemid 37464870)
60. Zoccali R, Muscatello MR, Bruno A, Cambria R, Micò U, Spina E, Meduri M: The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr Res 2007; 93:109-116 (Pubitemid 46817934)
61. Kremer I, Vass A, Gorelik I, Bar G, Blanaru M, Javitt DC, Heresco-Levy U: Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry 2004; 56:441-446 (Pubitemid 39195324)
62. Goff DC, Keefe R, Citrome L, Davy K, Krystal JH, Large C, Thompson TR, Volavka J, Webster EL: Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol 2007; 27:582-589 (Pubitemid 351339444)
63. Uzun O: Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report. J Psychopharmacol 2010; 24:425-427
64. Persaud R, Marks I: A pilot study of exposure control of chronic auditory hallucinations in schizophrenia. Br J Psychiatry 1995; 167:45-50 (Pubitemid 26124572)
65. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller J, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Brier A: Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163:790-799 (Pubitemid 44464525)
66. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H: Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59:921-928
67. Goff DC, Keefe R, Citrome L, Davy K, Krystal JH, Large C, Thompson TR, Volavka J, Webster EL: Childhood onset diagnoses in a case series of teens at clinical high risk for psychosis. J Child Adolesc Psychopharmacol 2009; 27:582-589
68. Preda A, Miller TJ, Rosen JL, Somjee L, McGlashan TH, Woods SW: Treatment histories of patients with a syndrome putatively prodromal to schizophrenia. Psychiatr Serv 2002; 53:342-344 (Pubitemid 34184690)
69. Rosen JL, Miller TJ, D'Andrea JT, McGlashan TH, Woods SW: Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophr Res 2006; 85:124-131
70. Meyer SE, Bearden CE, Lux SR, Gordon JL, Johnson JK, O'Brien MP, Niendam TA, Loewy RL, Ventura J, Cannon TD: The psychosis prodrome in adolescent patients viewed through the lens of DSM-IV. J Child Adolesc Psychopharmacol 2005; 15:434-451 (Pubitemid 41192830)